• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.01% Nasdaq Up0.26%

    Xenoport, Inc. (XNPT)

    6.39 Down 0.04(0.62%) 4:00PM EST
    |After Hours : 6.39 0.00 (0.00%) 4:00PM EST
    ProfileGet Profile for:
    Xenoport, Inc.
    3410 Central Expressway
    Santa Clara, CA 95051
    United States - Map
    Phone: 408-616-7200
    Website: http://www.xenoport.com

    Index Membership:N/A
    Full Time Employees:152

    Business Summary 

    XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders. It offers HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is in Phase I clinical trials for the treatment of psoriasis and relapsing forms of multiple sclerosis. In addition, it is developing arbaclofen placarbil product that is in Phase III clinical trials used for the treatment of spasticity in multiple sclerosis; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease has completed Phase II clinical trials. The company has a license agreement with Indivior PLC to develop and commercialize pharmaceutical products containing arbaclofen placarbil; license agreement with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan; and collaboration agreement with Glaxo Group Limited to develop and commercialize gabapentin enacarbil. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Xenoport, Inc.

    Corporate Governance 
    Xenoport, Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 10; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Vincent J. Angotti , 47
    Chief Exec. Officer and Director
    Mr. William G. Harris , 56
    Chief Financial Officer and Sr. VP of Fin.
    Mr. Gregory T. Bates D.V.M., 56
    Sr. VP of Regulatory Affairs & Quality
    Dr. Richard K. Kim M.D., 44
    Chief Medical Officer and Sr. VP of Clinical Devel. & Medical Affairs
    Mr. William J. Rieflin , 55
    Consultant and Director
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders